Bolt Biotherapeutics Inc
BOLT5.160USD
+0.005+0.10%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.90MMarket Cap
LossP/E TTM
More Details of Bolt Biotherapeutics Inc Company
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Bolt Biotherapeutics Inc Info
Ticker SymbolBOLT
Company nameBolt Biotherapeutics Inc
IPO dateFeb 05, 2021
CEOQuinn (William P)
Number of employees52
Security typeOrdinary Share
Fiscal year-endFeb 05
Address900 Chesapeake Drive
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16506659295
Websitehttps://boltbio.com/
Ticker SymbolBOLT
IPO dateFeb 05, 2021
CEOQuinn (William P)
Company Executives of Bolt Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
42.07K
+1932.37%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
30.45K
+6726.46%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
60.00
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
42.07K
+1932.37%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
30.45K
+6726.46%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
60.00
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
9.17%
Sofinnova Investments, Inc
7.18%
Pivotal Bioventure Partners Investment Advisor LLC
4.93%
Tang Capital Management, LLC
3.48%
Nan Fung Life Sciences
3.04%
Other
72.20%
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
9.17%
Sofinnova Investments, Inc
7.18%
Pivotal Bioventure Partners Investment Advisor LLC
4.93%
Tang Capital Management, LLC
3.48%
Nan Fung Life Sciences
3.04%
Other
72.20%
Shareholder Types
Shareholders
Proportion
Venture Capital
26.86%
Hedge Fund
5.82%
Individual Investor
5.02%
Investment Advisor
3.97%
Endowment Fund
1.87%
Investment Advisor/Hedge Fund
1.74%
Corporation
1.63%
Other
53.09%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
63
772.83K
55.30%
--
2025Q3
64
772.83K
55.30%
-83.50K
2025Q2
68
877.07K
57.63%
-28.77K
2025Q1
70
905.85K
57.45%
-195.46K
2024Q4
72
922.30K
57.57%
-37.66K
2024Q3
90
961.52K
86.05%
-192.50K
2024Q2
103
1.15M
86.54%
-71.25K
2024Q1
142
1.23M
94.72%
-580.30K
2023Q4
154
1.23M
96.73%
-60.00
2023Q3
174
1.23M
105.88%
-26.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vivo Capital, LLC
176.06K
9.17%
-1.00
-0.00%
Jun 30, 2025
Sofinnova Investments, Inc
137.72K
7.18%
-1.00
-0.00%
Jun 30, 2025
Pivotal Bioventure Partners Investment Advisor LLC
94.57K
4.93%
--
--
Jun 30, 2025
Tang Capital Management, LLC
166.88K
8.69%
-23.76K
-12.46%
Jun 30, 2025
Nan Fung Life Sciences
58.35K
3.04%
-1.00
-0.00%
Jun 30, 2025
Samsara BioCapital, LLC
52.46K
2.73%
-2.00
-0.00%
Jun 30, 2025
Quinn (William P)
2.06K
0.11%
--
--
Mar 31, 2025
Stanford Management Company
35.98K
1.87%
+1.00
+0.00%
Jun 30, 2025
The Vanguard Group, Inc.
58.48K
3.05%
-1.00
-0.00%
Jun 30, 2025
Pfizer Inc
31.30K
1.63%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 04, 2025
Merger
20→1
Date
Type
Ratio
Jun 04, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Bolt Biotherapeutics Inc?
The top five shareholders of Bolt Biotherapeutics Inc are:
Vivo Capital, LLC holds 176.06K shares, accounting for 9.17% of the total shares.
Sofinnova Investments, Inc holds 137.72K shares, accounting for 7.18% of the total shares.
Pivotal Bioventure Partners Investment Advisor LLC holds 94.57K shares, accounting for 4.93% of the total shares.
Tang Capital Management, LLC holds 166.88K shares, accounting for 8.69% of the total shares.
Nan Fung Life Sciences holds 58.35K shares, accounting for 3.04% of the total shares.
Vivo Capital, LLC holds 176.06K shares, accounting for 9.17% of the total shares.
Sofinnova Investments, Inc holds 137.72K shares, accounting for 7.18% of the total shares.
Pivotal Bioventure Partners Investment Advisor LLC holds 94.57K shares, accounting for 4.93% of the total shares.
Tang Capital Management, LLC holds 166.88K shares, accounting for 8.69% of the total shares.
Nan Fung Life Sciences holds 58.35K shares, accounting for 3.04% of the total shares.
What are the top three shareholder types of Bolt Biotherapeutics Inc?
The top three shareholder types of Bolt Biotherapeutics Inc are:
Vivo Capital, LLC
Sofinnova Investments, Inc
Pivotal Bioventure Partners Investment Advisor LLC
Vivo Capital, LLC
Sofinnova Investments, Inc
Pivotal Bioventure Partners Investment Advisor LLC
How many institutions hold shares of Bolt Biotherapeutics Inc (BOLT)?
As of 2025Q4, 63 institutions hold shares of Bolt Biotherapeutics Inc, with a combined market value of approximately 772.83K, accounting for 55.30% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Bolt Biotherapeutics Inc?
In --, the -- business generated the highest revenue for Bolt Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
